Since scientists began to mapped the human genome, Genes editing have always been the ultimate goalThe field idea if it seemed to be something from the scientific -fantastic novel, but it is here today and CRSPR Therapeutics AG NASDAQ: CRSP Leading pathField
CRISPR Therapeutics Today
CRISPR Therapeutics
As of 05/15/2025 21:00
- 52-week range
- $ 30.04
▼
$ 67.88
- Value is valuable
- $ 71.75
At the end of 2023, the company had a breakthrough when he He received the approval of CasgevyThe field is the first treatment for editing genes that will be approved. Casgevy addresses Sickle cell disease (SCD) And Beta-TalassemiaField
Nevertheless, CRSP shares are traded at about the same level as in 2018, and investors who bought shares in 2020 and 2021 hold a heavy bag if they are still involved in it. Many medical actions are risk, and this risk is more pronounced when investing in Biopharmaceutical companiesField
However, Casgevy is a powerful evidence of the concept, which will probably lead to Future approval of genes editingWith this means that the stage of combustion of funds can come to an end, and the company and CRSP shares growth It may be ready to start.
Monitor
Although the exact numbers are unknown, SCD affects millions around the worldIncluding about 100,000 in the United States. The World Health Organization (WHO) and the United Nations recognize that SCD is Global health problemField
In its last corporate presentation, the company announced that Casgevy is approved in eight jurisdictions And what does it have 65 authorized treatment centers (ATC) Activated all over the world. He expects that the new initiations of patients are growing significantly in 2025, and evaluates that the total addressable Casgevy market will be approximately 60,000.
However, the addressable market for SCD will be pale compared to diseases such as Cancer, diabetes and other autoimmune diseasesField Gene editING is focused on these long -term purposesAnd the company is currently participating in Five clinical trials and 10 preliminary testsField
That is why CRSPR is considering this as a transitional year. By 2026, he expects to generate enough Casgevy income to ensure sustainable growth For current and future clinical trials. As support, CRSPR notes that as of March 31, 2025, it had about 1.86 billion dollars. USA. balanceField
There is still time to buy CRSP shares
A The promise of genes editing is realThe field of reasonable investment in companies such as CRSPR Therapeutics Multi -turn potentialThe field but this day is not today.
CRISPR Therapeutics promotion today
$ 71.75
97.60% growthModerate purchase
Based on 18 analysts ratings
| The current price | $ 36.31 |
|---|---|
| High forecast | $ 120.00 |
| Average forecast | $ 71.75 |
| Low forecast | $ 32.00 |
CRISPR Therapeutics forecast forecast
One obstacle is The cost of these proceduresThe field is currently worth it about $ 2 million per dose of CasgevyDoctors can find a field A price tag Too hefty Compared to other effective methods of SCD.
In fact, since CRISPR has received permission to CRISPR-CAS9 at the end of 2023, shares was decreased by almost 50% and trading about five -year minimumsThere is a company Not yet profitable and generala small income worsens, which made an unattractive action during Higher interest ratesField Short interest remains high by about 25%Field
However 69% of CRSP shares belong to institutional investorsAnd the purchase was ahead of sale in each of the last nine quarters. A significant number of analysts also cover the CRSP shares. Analysts forecasts on Marketbeat have Moderate purchase rating for promotions With 71.75 dollars. Price This is more than 100% higher than the price of CRSP shares on May 15, 2025.
This tells you that CRSPR is not a rally of a memeField if you believe in Long -term genes editing potentialReasonable investments in CRSP shares with money that you can afford to use for speculation can lead to Big profit in the next 10 yearsField
Before considering CRISPR Therapeutics, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and Crispr Therapeutics was not on the list.
While CRISPR Therapeutics currently has a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Almost everyone loves strong shares that pay dividends, but high profitability can signal the danger. Open for yourself 20 high -profit dividend shares paying an unstable large percentage of their income. Enter your email address to get this report and avoid a high -profit dividend trap.
Get this free report